Your Location：
Home >
Browse articles >
The efficacy of tucatinib-based therapeutic approaches for HER2-positive breast cancer
REVIEW | Updated：2023-02-28
Previous|Next

    • The efficacy of tucatinib-based therapeutic approaches for HER2-positive breast cancer

    • Zaid Sirhan , Anita Thyagarajan , Ravi P. Sahu
    • Military Medical Research Vol. 9, Issue 5, Pages: 628-636(2022)

    • DOI： 10.1186/s40779-022-00401-3     

      CLC：

    Scan QR Code

  •  
  •  

  • Full Text(HTML)

  • Figs( 1 ) Tabs( 2 )

  • References

  • Publication Info

  • Metrics

Sections
icon
The trial reading is over, you can activate your VIP account to continue reading.
Deactivate >
icon
The trial reading is over. You can log in to your account, go to the personal center, purchase VIP membership, and read the full text.
Already a VIP member?
Log in >

19

Views

16

Downloads

0

CSCD

Alert me when the article has been cited
Submit
Tools
  • BibTeXDownload
  • EndnoteDownload
  • RefMan Download
  • NoteExpressDownload
  • NoteFirstDownload

Related Articles

Crosstalk in the brain tumor microenvironment: mechanisms, therapeutic strategies, and clinical advances
Accelerating global efforts to prevent women’s cancers
Reprogramming neural-tumor crosstalk: emerging therapeutic dimensions and targeting strategies
Immunotherapy for tuberculosis: current strategies and future directions
Metal-based nanomedicines for cancer theranostics

Related Author

Gui-Long Tanzhu
Liu Chen
Jiao-Yang Ning
Gang Xiao
Su Wen
Ce Wang
Hao Wen
Ke-Qin Zhang

Related Institution

Department of Oncology, Xiangya Hospital, Central South University
Department of Radiation Oncology, Hunan Cancer Hospital/Affiliated Hospital of Xiangya School of Medicine, Central South University
Xiangya Lung Cancer Center, Xiangya Hospital, Central South University
Department of Neuroscience, West Virginia University School of Medicine, Rockefeller Neuroscience Institute
Department of Pharmaceutical Sciences, West Virginia University School of Pharmacy